Company news
Genetic Signatures Ltd. (ASX:GSS) news
Every Genetic Signatures Ltd. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
FY26 Market Update
August 24, 2026
GSS responds to the BCAL Diagnostics Announcement
July 2, 2026
BCAL to Acquire Shares in Genetic Signatures
July 1, 2026
Danish Supply Agreement - Additional Information
April 15, 2026
Genetic Signatures Signs Danish Supply Agreement
April 14, 2026
Genetic Signatures Organisational Restructure
March 29, 2026
1H FY26 Results Release
February 25, 2026
1H FY26 Results Presentation
February 25, 2026
1H FY26 Appendix 4D and Half Year Report
February 25, 2026
GSS Appoints Anne Lockwood as Interim Managing Director
February 5, 2026
Genetic Signatures Appoints Maria Halasz as CEO
February 1, 2026
Quarterly Activities/Appendix 4C Cash Flow Report
January 19, 2026
Leadership Change at Genetic Signatures Limited
December 14, 2025
$4.4m R&D Tax Incentive Received
November 16, 2025
2025 Annual General Meeting Chair Address & Presentation
November 16, 2025
FY25 Market Update
August 24, 2025
FY25 Results Release
August 24, 2025
FY25 Appendix 4E and Annual Report
August 24, 2025
Strategic Partnership with Tecan and Repado
July 21, 2025
1H FY25 Market Update
February 25, 2025
Positive Momentum For The First Half Result
February 25, 2025
Half Yearly Report and Accounts
February 25, 2025
$5m R&D Tax Incentive Received
November 21, 2024
2024 AGM Chairman's Address and CEO Presentation
November 19, 2024
Appendix 4E and Annual Report
August 30, 2024
Despatch Of Retail Entitlement Offer Booklet
June 12, 2024
Completion of Institutional Entitlement Offer and Placement
June 5, 2024
FDA Clearance and Capital Raising Presentation
June 4, 2024
Genetic Signatures Announces $30 Million Capital Raising
June 3, 2024
FDA Clearance For Gastrointestinal Parasite Detection Kit
June 3, 2024
Genetic Signatures Appoints Allison Rossiter As CEO
June 3, 2024
Trading Halt
May 31, 2024
Decision to Cease Development of US Respiratory Product
May 26, 2024
Leadership Transition at Genetic Signatures
April 29, 2024
TGA authorises supply of updated Respiratory Detection Kit
April 21, 2024
1H 24 Market Update
February 21, 2024
Genetic Signatures Rights Issue Offer Booklet
January 1, 2024
Genetic Signatures Successfully Completes Placement
December 28, 2023
Genetic Signatures Announces $15.9m Capital Raising
December 20, 2023
Capital Raising Presentation
December 20, 2023
$6.9m R&D tax incentive received
December 18, 2023
2023 AGM Chairman's Address and CEO Presentation
November 28, 2023
Quarterly update and Appendix 4C
October 29, 2023
510(k) Filing in Preparation for US Commercial Launch
September 3, 2023
FDA 510(k) for Gastrointestinal Parasite Kit Submitted
September 3, 2023
Influenza B Detection Expected to Impact on Quarter Sales
August 24, 2023
Response to ASX Query
October 3, 2022
3base Kit for Antimicrobial Resistance Shows High Detection
September 28, 2022
Full Year Statutory Accounts
August 31, 2022
Clinical trial recruitment completed for US enteric kit
July 26, 2022